3 stories mentioning RAPPUpdated 10d ago
Every FINWIRES story that references RAPP, newest first.
Rapport Therapeutics (RAPP) has an average rating of buy and mean price target of $60.28, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Rapport Therapeutics (RAPP) has an average rating of buy and mean price target of $58.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Krishnaswamy Yeleswaram, Chief Development Officer, on April 10, 2026, sold 19,865 shares in Rapport Therapeutics (RAPP) for $695,823. Following the Form 4 filing with the SEC, Yeleswaram has control over a total of 266,651 common shares of the company, with 266,651 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2012593/000119312526154908/xslF345X05/ownership.xml
